Cargando…

Report on Use of a Methodology for Commissioning and Quality Assurance of a VMAT System

INTRODUCTION: Results of use of methodology for VMAT commissioning and quality assurance, utilizing both control point tests and dosimetric measurements are presented. METHODS AND MATERIALS: A generalizable, phantom measurement approach is used to characterize the accuracy of the measurement system....

Descripción completa

Detalles Bibliográficos
Autores principales: Mayo, Charles, Fong de los Santos, Luis, Kruse, Jon, Blackwell, Charles R., McLemore, Luke B., Pafundi, Deanna, Stoker, Joshua, Herman, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598853/
https://www.ncbi.nlm.nih.gov/pubmed/23554948
http://dx.doi.org/10.1371/journal.pone.0058877
Descripción
Sumario:INTRODUCTION: Results of use of methodology for VMAT commissioning and quality assurance, utilizing both control point tests and dosimetric measurements are presented. METHODS AND MATERIALS: A generalizable, phantom measurement approach is used to characterize the accuracy of the measurement system. Correction for angular response of the measurement system and inclusion of couch structures are used to characterize the full range gantry angles desirable for clinical plans. A dose based daily QA measurement approach is defined. RESULTS: Agreement in the static vs. VMAT picket fence control point test was better than 0.5 mm. Control point tests varying gantry rotation speed, leaf speed and dose rate, demonstrated agreement with predicted values better than 1%. Angular dependence of the MatriXX array, varied over a range of 0.94–1.06, with respect to the calibration condition. Phantom measurements demonstrated central axis dose accuracy for un-modulated four field box plans was ≥2.5% vs. 1% with and without angular correction respectively with better results for VMAT (0.4%) vs. IMRT (1.6%) plans. Daily QA results demonstrated average agreement all three chambers within 0.4% over 9 month period with no false positives at a 3% threshold. DISCUSSION: The methodology described is simple in design and characterizes both the inherit limitations of the measurement system as well at the dose based measurements that may be directly related to patient plan QA.